Drilldown: Medicines
Appearance
Use the filters below to narrow your results.
25B-NBOH (1) ·
25B-NBOMe (1) ·
25C-NBOH (1) ·
25C-NBOMe (1) ·
25I-NBOH (1) ·
25I-NBOMe (1) ·
25N-NBOMe (1) ·
2C-B (1) ·
2C-B-FLY (1) ·
2C-C (1) ·
2C-D (1) ·
2C-E (1) ·
2C-I (1) ·
2C-P (1) ·
2C-T-2 (1) ·
2C-T-7 (1) ·
Allylescaline (1) ·
Bromo-DragonFLY (1) ·
DOB (1) ·
DOC (1) ·
DOI (1) ·
DOM (1) ·
Escaline (1) ·
Methallylescaline (1) ·
Proscaline (1) ·
Sumatriptan / Naproxen (1) ·
TMA-2 (1)
5-HT2A agonist (12) ·
5-HT2A agonist; long duration (1) ·
5-HT2A agonist; MAO inhibitor (1) ·
5-HT2A agonist; milder than other 2C-x (1) ·
5-HT2A partial agonist (1) ·
Extremely potent 5-HT2A agonist; vasoconstrictor (1) ·
Extremely potent 5-HT2A agonist; very long duration (1) ·
Potent 5-HT2A agonist (5) ·
Potent 5-HT2A agonist; no oral activity (1) ·
Potent 5-HT2A agonist; very long duration (1) ·
Very potent 5-HT2A agonist; long duration (1) ·
'"`UNIQ--vote-000015CE-QINU`"' The dual-mechanism design exploits the inflammatory component of migraine that triptan monotherapy does not fully address. Risk of serotonin syndrome with SSRIs/SNRIs is theoretical but generally not seen clinically at triptan doses'"`UNIQ--ref-000015CF-QINU`"'. (1)
None (25) ·
[[USLegal:DEA Schedule I|Schedule I]] (United States) (1) ·
[[USLegal:Prescription only|Rx-only]] in US. NSAID-class '''Boxed Warning''' for CV thrombotic events and GI bleeding; triptans contraindicated in coronary artery disease, peripheral vascular disease, uncontrolled hypertension, and recent ergot or MAOI use'"`UNIQ--ref-000015D3-QINU`"' (1)
Showing below up to 27 results in range #1 to #27.


